Cardiac Biomarkers Market Size, Share and Growth Outlook, 2026

Cardiac Biomarkers Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Cardiac Biomarkers Market size is forecast to increase from $27.34 Billion in 2026 to $64.38 Billion in 2034 at a CAGR of 11.3% between 2026 and 2034.

The Cardiac Biomarkers market report provides detailed analysis and outlook of Cardiac Biomarkers segments including By Biomarker Type (Troponins, Creatine Kinase-MB, Natriuretic Peptides, Myoglobin, Ischemia-Modified Albumin, C-Reactive Protein ), By Application (Myocardial Infarction, Acute Coronary Syndrome, Congestive Heart Failure, Atherosclerosis), By Location of Testing (Laboratory Testing, Point-of-Care ), By End-User (Hospitals, Diagnostic Laboratories, Ambulatory Surgical Centers & Clinics, Home Healthcare Settings) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Cardiac Biomarkers Industry Overview

High-Sensitivity Troponin Assays Advancing Acute Myocardial Infarction Detection

The cardiac biomarkers industry continues to evolve through the development of increasingly sensitive diagnostic assays capable of identifying cardiovascular events at earlier stages. F. Hoffmann-La Roche Ltd reported primary results from its TSIX Study Program, validating the clinical performance of the Elecsys® Troponin T high-sensitivity Generation 6 assay. The CE Marked assay demonstrated enhanced sensitivity for detecting acute myocardial infarction (AMI) within three hours of emergency department presentation, supporting faster and more accurate clinical decision-making in acute care settings. A notable advancement within the assay is the introduction of sex-specific benchmark baseline troponin levels, reflecting growing recognition of biological differences that can influence cardiac biomarker interpretation. These developments highlight the industry's shift toward precision diagnostics that improve risk stratification, support earlier intervention, and enhance the accuracy of emergency cardiovascular assessments.

Point-of-Care Cardiac Biomarker Testing Accelerating Emergency Care Pathways

Rapid diagnostic capabilities are becoming increasingly important within the cardiac biomarkers market as healthcare providers seek to shorten evaluation timelines for patients presenting with suspected cardiac events. Abbott Laboratories expanded its cardiovascular diagnostics portfolio through the U.S. commercial launch of the i-STAT High Sensitivity Troponin-I test. The handheld point-of-care system is specifically designed to deliver rapid bedside cardiac biomarker analysis in emergency and acute care environments. By enabling high-sensitivity troponin measurements directly at the patient’s side, the platform supports accelerated heart attack rule-out protocols and facilitates timely clinical decision-making within critical treatment windows. The growing adoption of portable biomarker testing systems reflects increasing demand for decentralized diagnostic solutions that combine laboratory-quality performance with the speed and convenience required in emergency medicine and urgent care settings.

Portable Biomarker Platforms Expanding into Field-Based Cardiac Assessment

The application of cardiac biomarker testing is extending beyond traditional hospital environments into athletic and field-based healthcare settings. Siemens Healthineers established a collaboration with World Athletics to deploy advanced point-of-care diagnostic technologies at major endurance sporting events. The initiative incorporates portable testing platforms such as the Atellica VTLi patient-side immunoassay analyzer, which performs high-sensitivity cardiac troponin I measurements directly at event locations. These systems allow healthcare professionals to rapidly evaluate cardiac stress responses and biomarker fluctuations among athletes without requiring laboratory-based testing infrastructure. The integration of portable immunoassay technologies into active field settings demonstrates the expanding versatility of cardiac biomarker diagnostics and highlights growing opportunities for real-time cardiovascular monitoring in sports medicine, emergency response, and remote healthcare environments.

Cardiac Biomarkers Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Cardiac Biomarkers market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- F. Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens Healthineers AG, Danaher Corporation , QuidelOrtho Corporation, bioMérieux SA, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Randox Laboratories Ltd., PerkinElmer, Inc. (Revvity). The Cardiac Biomarkers market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Cardiac Biomarkers industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Cardiac Biomarkers Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Cardiac Biomarkers companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Cardiac Biomarkers markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Cardiac Biomarkers Market Competitive Benchmarking and Company Analysis

Leading companies in Cardiac Biomarkers industry include- F. Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens Healthineers AG, Danaher Corporation , QuidelOrtho Corporation, bioMérieux SA, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Randox Laboratories Ltd., PerkinElmer, Inc. (Revvity). The Cardiac Biomarkers market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Cardiac Biomarkers Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Cardiac Biomarkers market remains one of the strongest-performing segments in the country.
The US Cardiac Biomarkers Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Cardiac Biomarkers market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Cardiac Biomarkers industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Cardiac Biomarkers markets

Canada's strong Cardiac Biomarkers sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Cardiac Biomarkers market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Cardiac Biomarkers Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Cardiac Biomarkers market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Cardiac Biomarkers population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Cardiac Biomarkers industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Cardiac Biomarkers market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Cardiac Biomarkers sales through 2034

France Cardiac Biomarkers companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Cardiac Biomarkers Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Cardiac Biomarkers distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Cardiac Biomarkers Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Cardiac Biomarkers market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Cardiac Biomarkers industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Cardiac Biomarkers industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Cardiac Biomarkers Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Cardiac Biomarkers market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Cardiac Biomarkers market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Cardiac Biomarkers Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Cardiac Biomarkers Market Segmentation

By Biomarker Type
Troponins
Creatine Kinase-MB
Natriuretic Peptides
Myoglobin
Ischemia-Modified Albumin
C-Reactive Protein
By Application
Myocardial Infarction
Acute Coronary Syndrome
Congestive Heart Failure
Atherosclerosis
By Location of Testing
Laboratory Testing
Point-of-Care
By End-User
Hospitals
Diagnostic Laboratories
Ambulatory Surgical Centers & Clinics
Home Healthcare Settings

Top Companies in Cardiac Biomarkers Industry

F. Hoffmann-La Roche Ltd
Abbott Laboratories
Siemens Healthineers AG
Danaher Corporation
QuidelOrtho Corporation
bioMérieux SA
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories, Inc.
Randox Laboratories Ltd.
PerkinElmer, Inc. (Revvity)

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025